BELIEF trial published
The addition of bevacizumab to erlotinib improves progression-free survival for patients with advanced NSCLC harbouring activating EGFR and T790M mutation. Results from the BELIEF trial published in Lancet Respiratory Medicine: http://dx.doi.org/10.1016/S2213-2600(17)30129-7
6th ETOP Residential Workshop, 5-7 Oct, Amsterdam - Application open
Application is open for the 6th ETOP Residential Workshop taking place 5-7 October, 2017 in Amsterdam, The Netherlands.
The Lancet Summit: COPD and Lung Cancer
This new Summit, organised by The Lancet Respiratory Medicine and The Lancet Oncology, will cover all of the main areas of debate for patients with COPD and lung cancer from prevention, diagnosis, treatment through to palliative care.